Journals / Turkish Journal of Medical Sciences / 2021 / Cilt: 51 - Sayı: 4

Can treating critically-ill haematological malignancy patients in a separate intensive care unit decrease intensive care unit mortality?

Pages
2095–2100
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Thus, mortality rates of HM patients needing ICU care will decline.Key words: Intensive care unit, separate intensive care unit, patients with haematological malignancies, intensive care unit mortality

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aim: The aim of the study was to investigate whether treating haematological malignancy (HM) patients in a separate intensive care unit (ICU) would reduce ICU mortality.
📊
Key Findings & Data:Materials and methods: HM patients treated by the same ICU team in a general medical ICU (GM-ICU) and a separate haematology ICU (H-ICU) were included in this study.
💡
Conclusion & Impact:Thus, mortality rates of HM patients needing ICU care will decline.Key words: Intensive care unit, separate intensive care unit, patients with haematological malignancies, intensive care unit mortality
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background/aim: The aim of the study was to investigate whether treating haematological malignancy (HM) patients in a separate intensive care unit (ICU) would reduce ICU mortality. Materials and methods: HM patients treated by the same ICU team in a general medical ICU (GM-ICU) and a separate haematology ICU (H-ICU) were included in this study. Patients’ demographic characteristics and ICU data were recorded retrospectively. Differences in the ICU course and prognosis between these two groups were determined. Results: A total of 251 patients (102 from GM-ICU, 149 from H-ICU) were included in this study. The disease severity and organ failure scores at ICU admission and underlying HMs were not different between the two groups. Patients waited longer for admission to GMICU. Therapeutic procedures were performed significantly more frequently in GM-ICU. ICU complications were not different between the groups. ICU mortality rates were higher in GM-ICU (59.8% vs 37.6%, p = 0.006). Conclusion: A separate ICU allocated for haematology patients will allow timely and rapid admission of HM patients to ICU. Thus, mortality rates of HM patients needing ICU care will decline.Key words: Intensive care unit, separate intensive care unit, patients with haematological malignancies, intensive care unit mortality

🔖

Cite This Article

ÖZKURT, Z. N., YEGİN, Z. A., TÜRKOĞLU, M., DÜNDAR, N. B., AYGENCEL, G., YAĞCI, A. M. (2022). Can treating critically-ill haematological malignancy patients in a separate intensive care unit decrease intensive care unit mortality?. Turkish Journal of Medical Sciences, Cilt: 51 - Sayı: 4, 2095–2100. https://ajindex.com/articles/609454

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Thiéry G, Azoulay E, Darmon M, Ciroldi M, De Miranda S et al. Outcome of cancer patients considered for intensive care unit admission: a hospital-wide prospective study. Journal of Clinical Oncology 2005
  2. 23 (19): 4406-4413. doi: 10.1200/ JCO.2005.01.487 2. Aygencel G, Turkoglu M, Turkoz Sucak G, Benekli M. Prognostic factors in critically ill cancer patients admitted to the intensive care unit. Journal of Critical Care 2014
  3. 29 (4): 618-626. doi:10.1016/j.jcrc.2014.01.014 3. Soares M, Caruso P, Silva E, Teles JM, Lobo SM et al. Brazilian Research in Intensive Care Network (BRICNet). Characteristics and outcomes of patients with cancer requiring admission to intensive care units: a prospective multicenter study. Critical Care Medicine 2010
  4. 38 (1): 9-15. doi: 10.1097/ CCM.0b013e3181c0349e 4. Cherif H, Martling CR, Hansen J, Kalin M, Björkholm M. Predictors of short and long-term outcome in patients with hematological disorders admitted to the intensive care unit for a life-threatening complication. Supportive Care in Cancer 2007
  5. 15 (12): 1393-1398. doi: 10.1007/s00520-007-0268-1 5. Namendys-Silva SA, González-Herrera MO, García-Guillén FJ, Texcocano-Becerra J, Herrera-Gómez A. Outcome of critically ill patients with hematological malignancies. Annals of Hematology 2013
  6. 92 (5): 699-705. doi: 10.1007/s00277-013- 1675-7 6. Magid T, Haase N, Andersen JS, Nielsen OJ, Bonde J. Intensive care of haematological patients. Danish Medical Journal 2012
  7. 59 (3): A4395. PMID: 22381090 7. Bird GT, Farquhar-Smith P, Wigmore T, Potter M, Gruber PC. Outcomes and prognostic factors in patients with haematological malignancy admitted to a specialist cancer intensive care unit: a 5 yr study. British Journal of Anaesthesia 2012
  8. 108 (3): 452-459. doi: 10.1093/bja/aer449 8. Kalicińska, E, Kuszczak, B, Dębski J, Szukalski L, Wątek M et al. Hematological malignancies in Polish population: what are the predictors of outcome in patients admitted to Intensive Care Unit? Supportive Care in Cancer 2021
  9. doi: 10.1007/s00520-020-05480-3 9. Taccone FS, Artigas AA, Sprung CL, Moreno R, Sakr Y et al. Characteristics and outcomes of cancer patients in European ICUs. Critical Care 2009
  10. 13 (1): R15. doi: 10.1186/cc7713 10. Gordon AC, Oakervee HE, Kaya B, Thomas JM, Barnett MJ et al. Incidence and outcome of critical illness amongst hospitalised patients with haematological malignancy: a prospective observational study of ward and intensive care unit based care. Anaesthesia 2